Development of a gene panel for immune status assessment in sepsis
Authors' conclusion
The results support the potential utility of a four-gene panel to assess immune status and guide immunotherapy
Study context
- Population
- Patients with sepsis
- Comparison
- Four-gene panel (TBX21, GNLY, PRF1, IL2RB) for immune status assessment; immunotherapy effect by panel endotype
- Outcome
- Discriminatory power of four-gene panel (TBX21, GNLY, PRF1, IL2RB) for immune status
Methodological detailsmachine learning models, external validation, endotype analysis of double-blind randomised patients
- Machine learning models
- External validation
- Endotype analysis of double-blind randomised patients
Performance
As reported in the abstract
AUC in external validation across several machine learning models
0.891 to 0.909
Further findings
90-day mortality with immunotherapy within high-expression 4-gene panel endotype (subgroup)
| OR (95% CI) | ||
|---|---|---|
| HydrocortisoneHigher mortality | 12.46 (3.11–65.72) | |
| ThymosinHigher mortality | 4.17 (1.13–16.51) | |
| 0.050.21520Odds ratio (log scale) |
- 90-day mortality with immunotherapy within high-expression 4-gene panel endotype (subgroup): 99 double-blind randomized patients with sepsis clustered into two endotypes
90-day mortality with immunotherapy within high-expression 4-gene panel endotype (subgroup)
- Higher mortality with hydrocortisone or thymosin not observed in the other endotype
Original publication
Development of a gene panel for immune status assessment in sepsis. Ann Intensive Care. Published 27 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →